Clinical trials in Villejuif – page 37

929 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Villejuif at a glance

929

clinical trials

Research sites2

Quick filters

929 trials in Villejuif

Open in trial search

Pancreatic neuroendocrine tumour

Not yet recruiting

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Institut Gustave Roussy

Contact Research Centre

Colorectal cancer

Not yet recruiting

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo

Study of denikitug alone or in drug combination in adults with advanced microsatellite stable colorectal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Gilead Sciences Inc.

Contact Research Centre

Colorectal cancer metastatic

Not yet recruiting

Postoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence

Registered drugNo placebo

Postoperative oxaliplatin liver‑directed chemotherapy plus drug combination in patients with resected colorectal liver metastases at high risk of recurrence

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Levofolinate
Sponsor:Unicancer

Contact Research Centre

Ovarian cancer

Not yet recruiting

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Arcagy Gineco

Contact Research Centre

T-cell type acute leukaemia

Not yet recruiting

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo

Evaluating venetoclax with drug combination in relapsed/refractory T‑cell acute lymphoblastic leukemia patients

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Centre Hospitalier De Versailles

Contact Research Centre

Breast cancer+2

Not yet recruiting

Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

Registered drugNo placebo

Prifetrastat (PF-07248144) Plus Fulvestrant in Adults With Advanced HR+/HER2- Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitor Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:Unicancer

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Assistance Publique Hopitaux De Paris

Contact Research Centre

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Pfizer Inc.

Contact Research Centre

Squamous cell carcinoma of head and neck+1

Not yet recruiting

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of PTT-4256 and nivolumab in patients with solid tumors.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Pathios Therapeutics Limited

Contact Research Centre

Neuroendocrine carcinoma metastatic

Not yet recruiting

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo

A study of irinotecan, fluorouracil, calcium folinate, zimberelimab, and domvanalimab for patients with metastatic gastro-enteropancreatic neuroendocrine carcinoma.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Hospices Civils De Lyon

Contact Research Centre

Pancreatic carcinoma metastatic+1

Not yet recruiting

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Ponsegromab
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

NBTXR3 with radiotherapy
EGFR-ADC therapy combinations
HPV-positive oropharyngeal cancer

02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

Anti-CEACAM5 ADC therapy
Sotorasib combinations
Novel gastrointestinal cancer treatments

03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

Elranatamab-lenalidomide therapy
Belantamab mafodotin combinations
T-cell lymphoma treatments

04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

Novel antibody-drug conjugates
Microbiome-based approaches
Targeted therapy combinations

05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

PARG inhibitor studies
Targeted molecular therapies
Immunotherapy combinations

Back to France All countries